PHAR 301 Lecture Notes - Lecture 21: White Blood Cell, Docetaxel, Microtubule

• School: McGill University
• Department: Pharmacology and Therapeutics
• Course: PHAR 301
• Professor: Barbara Hales

Document Summary

Combination chemotherapy: provides maximal cell kill with tolerable toxicity, provides a broader range of interactions between drugs and tumour cells, may prevent or slow the development of resistance. Hodgkin lymphoma - mopp: mechlorethamine - the very reactive nitrogen mustard, vincristine (o) - alkaloids, procarbazine - alkylating agent; more selective when tumours are hypoxic, prednisone - glucocorticoids. Non-hodgkin lymphoma - chop: cyclohosphamide - alkylating agent, doxorubicin (h) - anti-tumour antibiotic, vincristine (o, prednisone. Hormonal manipulations: glucocorticoid action - prednisone, block estrogen action - tamoxifen, anastrozole, block androgen action - flutamine, finasteride. In all cases, the tumour cells have to have the hormone dependence, e. g. estrogen/androgen/glucocorticoid receptor. Prednisone will bind to the glucocorticoid receptor and affect the expression of genes that are turned on when the glucocorticoid receptor binds to the promoter. A lot of anti-inflammatory genes and genes that regulate things like cell death are turned on.